Archives

img-01

China Further Expedites Innovative Drug Approvals in Greater Bay Area and Yangtze River Delta

In late October, China’s NMPA announced that they had started a new program in 2 locations to simplify the process for the approval of innovative drugs. “Advanced Acceptance Services” will become available for applications qualified for priority review or conditional approval as early as November 1, 2024 – following appropriate pre-application consultations.... Read More

img-01

China Becoming a Leader in Precision Oncology

China is rapidly becoming a key driver in the development of precision oncology drugs, facilitated by its rising cancer incidence, proactive government policies, and an influx of biopharma investment. China accounted for nearly a quarter of all global cancer diagnoses, with about 5 million... Read More